1. Medtech Insight
  2. >>Business
  3. >>Strategy

Eight Things That Will Fix Medtech Investing

The last five years have been brutal ones for medical device VCs and entrepreneurs, yet there’s still cause for hope. In a series of interviews, we asked venture capitalists, entrepreneurs, and executives: what gives you hope and what makes you optimistic about the future of medtech?

The timing of the news could not have been worse. In January, just a few days before the health care industry was set to meet at the JP Morgan Healthcare Conference in San Francisco, renal denervation – one of the highest profile sectors in medtech – imploded on news that Medtronic PLC’s Symplicity hypertension device didn’t perform well in clinical studies. The news was a kick in the face to an investment sector already on its hands and knees. (See Also see "SYMPLICITY Results Make Life Difficult For Renal Denervation Programs" - In Vivo, 24 January, 2014..) Dissemination of the disappointing trial results happened to coincide with the meteoric post-IPO performance of Intercept Pharmaceuticals Inc., yet another success story that just highlighted the differences between the medtech and biopharmaceutical sectors.

Where did things go so wrong? Clearly, the Symplicity trial results are something future device VCs and executives will see...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Fallouh Healthcare Receives Grant Funding From Innovate UK

 
• By Natasha Barrow

Fallouh Healthcare has received £305,050 in grant funding from Innovate UK as part of the European Union’s Eureka Eurostars program. The company aims to detect cardiac tamponade, a condition that affects patients after heart surgery. Currently, there is no way to accurately diagnose the condition.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 
• By Natasha Barrow

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

UK MHRA Joins New Global Network For Safe Use Of AI In Healthcare

 
• By Natasha Barrow

The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.

Home-Testing Added To UK National Cervical Cancer Screening Program

 
• By Natasha Barrow

NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.

More from Business

UK MHRA Joins New Global Network For Safe Use Of AI In Healthcare

 
• By Natasha Barrow

The UK's regulatory agency is the first to join a new international network for oversight of AI in healthcare run by a non-profit organization, HealthAI, the global agency for responsible AI in health.

Home-Testing Added To UK National Cervical Cancer Screening Program

 
• By Natasha Barrow

NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.

ADA 2025: Tandem Becomes Abbott’s Fourth Partner In Push To Advance Dual Sensor CGM Strategy

 
• By Marion Webb

Ahead of the ADA conference, Abbott announced Tandem as the fourth partner to integrate Abbott’s dual glucose-ketone sensor with automated insulin delivery. Expanded Medicare CGM coverage, FDA label expansions and new ADA guidelines position Abbott to grow its CGM footprint in a competitive market.